Premium
Efficacy of venlafaxine in mixed depression‐anxiety states
Author(s) -
Gorman Jack M.,
Papp Laszlo A.
Publication year - 2000
Publication title -
depression and anxiety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.634
H-Index - 129
eISSN - 1520-6394
pISSN - 1091-4269
DOI - 10.1002/1520-6394(2000)12:1+<77::aid-da10>3.0.co;2-1
Subject(s) - venlafaxine , anxiety , depression (economics) , antidepressant , psychology , psychiatry , venlafaxine hydrochloride , generalized anxiety disorder , anxiety disorder , comorbidity , clinical psychology , medicine , economics , macroeconomics
Patients with depression almost always suffer from comorbid anxiety or anxiety disorder. It is commonly stated that comorbid depression and anxiety has a worse prognosis, even with adequate therapy, than depression alone. An accumulation of data now make clear that the antidepressants venlafaxine and venlafaxine XR are effective in reducing anxiety in patients with depression. Several of the studies supporting this are reviewed here. Venlafaxine and venlafaxine XR have also been shown to be effective in treating anxiety disorders and venlafaxine XR is presently the only antidepressant approved by the FDA for the specific treatment of generalized anxiety disorder. The effectiveness of venlafaxine in treating anxiety associated with depression and anxiety disorders supports theories implicating abnormal noradrenergic activity as a component of pathological anxiety. Depression and Anxiety, Volume 12, Supplement 1:77–80, 2000. © 2000 Wiley‐Liss, Inc.